Axa S.A. Amicus Therapeutics, Inc. Transaction History

Axa S.A.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$9.2 - $23.86 $3.12 Million - $8.1 Million	-339,638 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$13.47 - $24.89 $2.71 Million - $5 Million	-200,868 Reduced 37.16%	339,638 $7.84 Million
Q3 2020 Nov 13, 2020	SELL	$12.89 - $15.89 $551,086 - $679,345	-42,753 Reduced 7.33%	540,506 $7.63 Million
Q2 2020 Aug 14, 2020	SELL	$8.86 - $15.69 $1.54 Million - $2.73 Million	-173,764 Reduced 22.95%	583,259 $8.8 Million
Q1 2020 May 15, 2020	SELL	$6.63 - $11.16 $4.78 Million - $8.05 Million	-721,087 Reduced 48.78%	757,023 $7 Million
Q4 2019 Feb 18, 2020	BUY	$7.48 - $10.75 $130,137 - $187,028	17,398 Added 1.19%	1,478,110 $14.4 Million
Q3 2019 Nov 14, 2019	BUY	$8.02 - $13.25 $592,333 - $978,605	73,857 Added 5.33%	1,460,712 $11.7 Million
Q2 2019 Aug 13, 2019	BUY	$10.96 - $14.4 $97,861 - $128,577	8,929 Added 0.65%	1,386,855 $17.3 Million
Q1 2019 May 14, 2019	BUY	$10.04 - $13.92 $1.6 Million - $2.22 Million	159,235 Added 13.07%	1,377,926 $18.7 Million
Q3 2018 Nov 08, 2018	BUY	$11.6 - $16.54 $7.5 Million - $10.7 Million	646,739 Added 113.08%	1,218,691 $14.7 Million
Q2 2018 Aug 13, 2018	BUY	$13.13 - $17.09 $793,747 - $1.03 Million	60,453 Added 11.82%	571,952 $8.93 Million
Q1 2018 May 14, 2018	SELL	$13.76 - $17.12 $89,316 - $111,125	-6,491 Reduced 1.25%	511,499 $7.69 Million
Q4 2017 Feb 13, 2018	SELL	$12.51 - $16.24 $2,276 - $2,955	-182 Reduced 0.04%	517,990 $7.45 Million
Q3 2017 Nov 13, 2017	BUY	$11.74 - $15.78 $6.08 Million - $8.18 Million	518,172	518,172 $7.81 Million

311

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.7B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.